Clinical Validation of Cytocell Pathology Probes
|
|
- Annabelle Goodwin
- 6 years ago
- Views:
Transcription
1 Clinical Validation of Cytocell Pathology Probes Shivanand Richardson Specialized Technician Molecular Pathology Department of Pathology, University Medical Center Utrecht The Netherlands 5th annual Cytocell FISH User Group Meeting 2017
2 Molecular Pathology UMC Utrecht
3 Disclosures Collaboration with Cytocell
4 Content FISH diagnostics at University Medical Center Utrecht Cytocell Project workflow at University Medical Center Utrecht CytoVision Scanning and Image Analysis Clinical Validation of Cytocell Pathology Probes
5 Cytocell UMC Utrecht collaboration Cytocell Designs and manufactures FISH probes Validate FISH probes on patient material Designs new probes for new diagnostic purposes Quality requirements (ISO certification) clinical evaluation UMC Utrecht JCI Accredited institute Pathology department ISO-norm Experienced with FISH Cannot give away patient material Continuous improvement in FISH diagnostics Collaboration essential for creating and validating new FISH probes
6 Cytocell UMC Utrecht collaboration Pathology department of UMC Utrecht conducted clinical validation of FISH probes (provided by Cytocell) on patient material relevant for that probe. With this collaboration Cytocell has a partner for probe validation on patient material, and UMC Utrecht would be the first to have new validated probes in a diagnostic setting.
7 Molecular Pathology UMC Utrecht Mutation analysis NGS, Sanger, HRM Translocations FISH, RT-PCR CNV Copy number variation MLPA, FISH, SNP array Molecular Pathology UMC Utrecht HPV Human papillomavirus Methylation Array, MS-MLPA MSI Microsatellite instability B- and T- cel clonality
8 Content FISH diagnostics at University Medical Center Utrecht Cytocell Project workflow at University Medical Center Utrecht CytoVision Scanning and Image Analysis Clinical Validation of Cytocell Pathology Probes
9 UMC Utrecht FISH workflow Day 1 FISH Request (LMS) Evt. Slide sectioning HE scoring (tumor area & percentage) FISH slide in oven FISH starts 14:00, pretreatment, area marking on glass and probe o/n FISH: Monday Thursday (entire workflow) Friday (image analysis + report) FISH results: Within 2-3 days Max. 1 week (repeat analysis) Day 2 FISH stringent wash, DAPI + Cytovision scanning CytoVision analysis of images (technician + KMBP) CytoVision pdf report in UDPS (KMBP) (Uniform Decentralized System PALGA) Autorisation in UDPS (pathologist) Min. 40 FISH requests per week Daily max. 28 FISH slides (routine diagnostics + Cytocell FISH validation)
10 UMC Utrecht FISH Normal Deletion Breakapart Amplification ALK BCL2 BCL6 CEP6 CHOP cmet cmyc b.a. cmyc fusion COL1A/P DGFRB CCND1 ETV6 EWSR1 FGFR1 FGFR3 FKHR (FOXO1) FUS HER2 MALT MAML2 MDM2 MUM1 MYB NMYC PLAG-1 RET ROS1 SYT (SS18) 32 FISH Probes for diagnostic use Various manufacturers (Cytocell, Vysis, Zytolight) 1 FISH protocol (in-house method) TFE3 USP6 X-Y-18 YWHAE
11 UMC Utrecht FISH amounts
12 UMC Utrecht FISH diagnostics started 2008 LeicaDM5500 manual microscoop +LASX software Scanner Validated on 75 FISH cases Leica DM6000 Scanner + CytoVision software FISH diagnostics since 2014
13 Manual microscope vs Scanner RET Cytocell -Manual RET Cytocell -Scanner 100x 63x
14 Content FISH diagnostics at University Medical Center Utrecht Cytocell Project workflow at University Medical Center Utrecht CytoVision Scanning and Image Analysis Clinical Validation of Cytocell Pathology Probes
15 Cytocell Project Cytocell Defines the list of probes and references Phase 1 UMC Utrecht reviews the list of probes discusses/agrees with Cytocell checks the availability of tissue Cytocell probe and reference probe were tested per patient simultaneously Phase 2
16 Workflow Cytocell Project Request Receive FISH Probe request from Cytocell Tissue Pathologist advices what type of tissue to use Tissues is requested and provided by Biobank Tissue Facility UMC Utrecht FISH Slides sectioning, HE (tumor evaluation by pathologist) and FISH FISH is performed by trained technicians Analysis Imaging with scan microscope (or by manual microscope) Image analysis and scoring detailed categories Report results Images and results are evaluated by Clinical Molecular Biologist in Pathology Report Scoring results provided to Cytocell Digital Image are provided to Cytocell Clinical evaluation report
17 Workflow diagram FISH probe validation Order reference probe Register in probe database Test on normal tissue (check if concordant to datasheet) Determine tumor test tissue Request test tissue Slide Sectioning Conduct FISH Image analysis and report Use of FISH scanner Use of TMA
18 Workflow diagram Probe validation Use of FISH scanner Marked FISH processed slide Determine Tumor area and percentage in HE Determine scan method based on tumor percentage, cell density and sample size Imaging (Manual, Semiautomatic or Automatic) Scoring / Results Use of TMA
19 Workflow diagram Probe validation Use of FISH scanner Use of TMA Request TMA Tissue selection in UDPS Slide sectioning for HE Tumor area selection on HE Submit marked slides and FFPE blocks TMA is designed and made TMA slide sectioning Tumor evaluation in HE Benefits: Less probe needed Specific tumor area Image analysis with different probes in same region
20 TMA Colon/ Lung / Tonsil
21 TMA NSCLC cases
22 Content FISH diagnostics at University Medical Center Utrecht Cytocell Project workflow at University Medical Center Utrecht CytoVision Scanning and Image Analysis Clinical Validation of Cytocell Pathology Probes
23 Scanning preparation Marking of tumor area on FISH slide. Automatic scanning: Mandatory for automatic region detection. Case 1 Case 1 Case 1 Case 1 HE FISH Semi-automatic: Guidance for manual region selection.
24 Manual scoring with detailed categories Frequently > 40 categories Extremely long Excel datasheets Labor intensive Error prone
25 CytoVision probe templates Standardized diagnostic scoring +/- 8 categories Cell monitoring (aberrant cells)
26 Break-apart spot counting configuration +
27 Break- Apart FISH spot counting configuration +
28 Region Markup Case 1
29 Region Markup Case 1
30 Region Markup Case 1
31 Region Markup Case 1
32 Region Markup Case 1
33 Scanning Case 1
34 Case analysis Case 1
35 Case analysis Case 1
36 Case analysis Case 1
37 Case analysis Case 1
38 Case analysis Case 1
39 Case analysis Case 1
40 Case analysis Case 1
41 Case analysis Case 1
42 Case analysis Case 1
43 Content FISH diagnostics at University Medical Center Utrecht Cytocell Project workflow at University Medical Center Utrecht CytoVision Scanning and Image Analysis Clinical Validation of Cytocell Pathology Probes
44 Cytocell Project Phase 1
45 Frequency of genomic alterations in lung adenocarcinoma
46 ALK break-apart probe (LPS019) Intended purpose: To identify FISH rearrangements of ALK gene on chromosome 2 in patients with Non-small-cell lung carcinoma. Test tissue: Lung Primary and Metastatic tissue Aberrant cells: break apart and single red ALK cut off criteria : <10% not translocated, 10%-15% equivocal (translocation unlikely), >15% translocation Round 1 Round 2 Reference method - Vysis ALK break-apart probe (06N38-020) Source of material Archive slides TMA Patients tissue N=28 10 positive for translocation Control tissue N=8 N=5 Result Positive cases showed breakapart and single red signals N=22 1 positive for translocation 100% Concordant results between Cytocell probe and reference method
47 Phase 1- ALK ALK Cytocell ALK Vysis
48 ROS1-GOPC (FIG) break-apart/deletion probe (LPS046) Intended purpose: To identify FISH rearrangements of ROS1 gene on chromosome 6 in patients with Non-small-cell lung carcinoma. Test tissue: Lung Primary and Metastatic tissue Aberrant cells: break apart and single green ROS1-GOPC (FIG) cut off criteria : <10% not translocated, 10%-15% equivocal (translocation unlikely), >15% translocation Round 1 Round 2 Reference method - Kreatech ROS1 (6q22) breakapart probe (KBI-10752) Source of material Archive slides TMA Patients tissue N=26 4 positive for translocation Control tissue N=5 N=5 Result Positive cases showed breakapart and single green signals N=22 2 positive for translocation 3 cases discordant, increased background and weak signal with Kreatech probe
49 Phase 1 ROS1- GOPC (FIG) ROS1 Cytocell ROS1 Kreatech
50 RET break-apart probe (LPS045) Intended purpose: To identify FISH rearrangements of RET gene on chromosome 10 in patients with Non-small-cell lung carcinoma. Test tissue: Lung Primary and Metastatic tissue Aberrant cells: break apart and single red RET cut off criteria : <10% not translocated, 10%-15% equivocal (translocation unlikely), >15% translocation Round 1 Round 2 Reference method - ZytoLight SPEC RET Dual Color break-apart probe (Z ) Source of material Archive slides TMA Patients tissue N=24 2 positive for translocation Control tissue N=5 N=5 Result Positive cases showed breakapart and single red signals N=22 0 positive for translocation RET translocations are very rare <2% 100% Concordant results between Cytocell probe and reference method
51 Phase 1 RET RET Cytocell RET ZytoLight
52 Phase 1 ALK / ROS1 / RET Probe Remarks Moderate Good signal quality. Increased background caused by collagen in Lung tissue. Cellient (Cytological material) displayed increased background. Signal strength varies per case and per probe. ROS1 probe frequently display 1 signal pair per cell. Overall, the ALK, ROS1 and RET Cytocell probe works good enough for diagnostic purposes, as compared to the reference probes.
53 Cytocell Project Phase 2
54 TFE3 break-apart probe (LPS051) Intended purpose: To identify FISH rearrangements of TFE3 gene on the X chromosome in patients with Renal Cell Carcinoma. Test tissue: Renal (kidney) Aberrant cells: break apart Aberrant signal pattern gender specific: Male (XY): break-apart single red and single green signal (no fusion pair) Female (XX): fusion pair + break-apart single red and single green signal TFE3 cut off criteria : 10% translocation Reference method Source of material Round 1 ZytoLight SPEC TFE3 Dual Color break-apart probe (Z ) Sectioned slides Patients tissue N=25 1 positive for translocation (rare translocation) Control tissue Result N=7 (tonsil) 100% Concordant results between Cytocell probe and reference method
55 Phase 2 TFE3 TFE3 Cytocell TFE3 ZytoLight
56 Phase 2 TFE3 probe remarks All cases concordant. Moderate Good signal quality. Interpretation in low quality tissue material is difficult. Signal strength varies per case. Overall, the Cytocell TFE3 (LPS051) probe works good enough for diagnostic purposes, as compared to the ZytoLight probe.
57 FOXO1(FKHR) break-apart probe (LPS049) Intended purpose: To identify FISH rearrangements of FOXO1 gene on chromosome 13 in patients with Alveolar Rhabdomyosarcoma. Test tissue: Sarcoma Aberrant cells: break apart FOXO1 cut off criteria : 10% translocation Reference method Source of material Round 1 Vysis FOXO1 break-apart probe (03N60-020) Sectioned slides Patients tissue N=22 3 positive for translocation Control tissue Result N=7 (tonsil) 100% Concordant results between Cytocell probe and reference method
58 Phase 2 FOXO1 FOXO1 Cytocell FOXO1 Vysis
59 Phase 2 FOXO1 probe remarks All cases concordant. Moderate Good signal quality. Interpretation in low quality tissue material is difficult. Signal strength varies per case. Overall, the Cytocell FOXO1 (LPS049) probe works good enough for diagnostic purposes, as compared to the Vysis probe.
60 FUS break-apart probe (LPS050) Intended purpose: To identify FISH rearrangements of FUS gene on chromosome 16 in patients with a Soft Tissue Sarcoma. Test tissue: Sarcoma Aberrant cells: break apart FUS cut off criteria : 10% translocation Reference method Source of material Round 1 Vysis FUS break-apart probe (03N58-020) Sectioned slides Patients tissue N=28 13 positive for translocation Control tissue Result N=7 (tonsil) 1 case discordant, 7 cases not interpretable
61 Phase 2 FUS FUS Cytocell FUS Vysis
62 Phase 2 FUS probe remarks Moderate signal quality Most cases concordant 27 cases concordant, 1 case discordant. discordance: Cytocell: 6% break-apart - no translocation Vysis: 45% break-apart- translocation High background signals and weak FISH signal with both probes. 7 cases not interpretable: Cytocell: 7 cases Vysis: 3 cases Interpretation in low quality tissue is more difficult using the Cytocell FUS break apart probe, although the Vysis probe gives in some cases still a weak but interpretable signal. If a sample shows too much background and weak fluorescent signal, do not try to interpret the FISH signals -> Repeat analysis.
63 Take home message FISH diagnostics can be fast, accurate and robust Standardized protocols are essential for FISH diagnostics High throughput & automated image analysis is validated Critical clinical evaluation on tissue samples is necessary
64 Cytocell project Collaboration Cytocell: Kerry McKenna (Study Co-ordinator) Darleen Welford (Director of Regulatory Compliance) Steve Chatters (Senior Product Manager Pathology) Stewart Kennedy UMCU, Pathology: Roel de Weger Stefan Willems Ton Peeters Petra van der Weide Kevin van der Ven Manon Huibers TICO europe: Tessa Vermeer Marie-Christine Vierhout Shivanand Richardson
65 Molecular Pathology UMC Utrecht
66
HSL-Advanced Diagnostics 2018 / 19 Test & Service List
HSL-Advanced Diagnostics 2018 / 19 Test & Service List 2018/19 TEST & SERVICE LIST Haematoxylin & Eosin H&E H&E per slide Routine Immunohistochemistry Immunohistochemical demonstration of an antigen in
More informationMolecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA
Molecular Genetics of Paediatric Tumours Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Financial Disclosure NanoString - conference costs for
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationDako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)
INTERPRETATION Dako Agilent Pathology Solutions IQFISH Interpretation Guide ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis) IT S ABOUT TIME For In Vitro Diagnostic Use ALK, ROS1,
More informationSignificance of Chromosome Changes in Hematological Disorders and Solid Tumors
Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome 3.3 X 10 9 DNA basepairs Estimated genetic constitution 30,000
More informationSignificance of Chromosome Changes in Hematological Disorders and Solid Tumors
Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome! Estimated genetic constitution! Size of average chromosome
More informationOncology Cytogenetics Diagnostic Service - User Guide 2014
Oncology Cytogenetics Diagnostic Service - User Guide 2014 Contact details Address: Cytogenetics Department 5 th Floor Tower Wing Guy s Hospital Great Maze Pond London SE1 9RT General enquiries 0207 188
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationTESTING OF ROS1-POSITIVE TUMORS BY IHC DISPLAYS A FISH-POSITIVE SUBGROUP WHICH MIGHT NOT BENEFIT FROM RECENTLY APPROVED DRUG THERAPY
TESTING OF ROS1-POSITIVE TUMORS BY IHC DISPLAYS A FISH-POSITIVE SUBGROUP WHICH MIGHT NOT BENEFIT FROM RECENTLY APPROVED DRUG THERAPY Vanessa Rüsseler,MD Institut of Pathologie Uniklinik Köln Disclosure
More informationYour single-source laboratory solution. FISH Probe Library
Your single-source laboratory solution. FISH Probe Library Alphabetical List by Probe with Clinical Indication Probe Clinical Indication 1p36 (TP73)/19q13 (GLTSCR) 1q21 (CKS1B) 5q (CSF1R/RPS14) 7q (MDFIC)
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationFusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas
Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Igor Astsaturov Philip Ellis Jeff Swensen Zoran Gatalica David Arguello Sandeep Reddy Wafik El-Deiry Disclaimers Dr. Igor
More information(Fully automated FISH Analysis for B-cell Chronic Lymphocytic Leukemia: a faster alternative to manual double scoring)
Routine integration of fully automated image analysis of Kreatech CLL FISH Probes, using the CytoVision GSL Scanning System (Fully automated FISH Analysis for B-cell Chronic Lymphocytic Leukemia: a faster
More informationOncology Genetics: Cytogenetics and FISH 17/09/2014
Oncology Genetics: Cytogenetics and FISH 17/09/2014 Chris Wragg Head of Oncology Genomics, BGL BGL Bristol Genetics Laboratory (BGL) CPA accredited Genetics laboratory serving a core population of 4-5million
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationQuality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024
Quality in Control ROS1 Analyte Control Product Codes: HCL022, HCL023 and HCL024 Contents What is ROS1? 2 The Role of ROS1 in Cancer 3 ROS1 Assessment 3 ROS1 Analyte Control Product Details 4 ROS1 Analyte
More informationDisclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
More informationCentral Pathology Review and Tissue MicroArrays. Dr Lisa Storer Children s Brain Tumour Research Centre Nottingham
Central Pathology Review and Tissue MicroArrays Dr Lisa Storer Children s Brain Tumour Research Centre Nottingham What is a tissue microarray? Tissue microarrays (TMAs) consist of paraffin blocks in which
More informationCytogenetics 101: Clinical Research and Molecular Genetic Technologies
Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationBreast Cancer Interpretation Guide
Breast Cancer Interpretation Guide UCT D O R P NEW ERBB2/ C E P S ht e ZytoLig lor Prob o C l a u 2D D17S12 ng to the i d r o c c a ting for re-tes idelines 2013 ASCO Gu Breast Cancer Interpretation Guide
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationFor finding your local dealer visit
Catalogue 2017 For finding your local dealer visit DISCLAIMER All information is supplied without liability. All product data are subject to changes. The information contained herein is believed to be
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationP323-B1 CDK4-HMGA2-MDM2
SALSA MLPA probemix P323-B1 CDK4-HMGA2-MDM2 Lot B1-0714, B1-0711. As compared to previous test version (lot A1-0508), this probemix has been completely redesigned. Probes for HMGA2 and several other genes
More informationGenetics Quality and Accreditation workshop Manchester 17 th May 2017
Genetics Quality and Accreditation workshop Manchester 17 th May 2017 Katrina Rack Oxford CEQAS What is CEQAS Types of schemes Scheme update Highlights 2016 Key recommendations CEQAS Background External
More informationDisclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
More informationHER2 FISH pharmdx TM Interpretation Guide - Breast Cancer
P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment
More informationThe new Leeds Solid Tumour Molecular Oncology Diagnostics Service. Paul Roberts, Genetics, Leeds
The new Leeds Solid Tumour Molecular Oncology Diagnostics Service Paul Roberts, Genetics, Leeds Molecular Oncology services pre-2013 DNA lab Germline cancer Cytogenetics lab FISH, cell culture, molecular
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationFinancial disclosures
An update on immunohistochemical markers in mesenchymal neoplasms By Konstantinos Linos MD, FCAP, FASDP Assistant Professor of Pathology Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical
More informationOverview of the ESP Lung and Colon EQA schemes with a focus on Dutch laboratories
Overview of the ESP Lung and Colon EQA schemes with a focus on Dutch laboratories Dr. Nils t Hart University Medical Center Groningen, The Netherlands Drs. Cleo Keppens Catholic University of Leuven, Belgium
More informationCopy number and somatic mutations drive tumors
Detection of copy number alterations, ploidy and loss of heterozygosity across the genome in FFPE specimens Utility for diagnosis and treatment with comparison to FISH-based and as a complement to sequencing
More informationFluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)
PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green
More informationCLL Complete SM Report
Reported: 02/01/2012 Σ CGI ID No:5 Client:r Client Address: CLINICAL DATA: Lymphoma No CBC results provided. CLL Complete SM Report FINAL DIAGNOSIS: CD19+ B cell lymphoma, ZAP-70 + (44%), with borderline
More informationMRC-Holland MLPA. Description version 06; 07 August 2015
SALSA MLPA probemix P323-B1 CDK4-HMGA2-MDM2 Lot B1-0711. As compared to version A1 (test version sent to test labs), this product has been completely redesigned. Probes for HMGA2 and several other genes
More informationAmerican Society of Cytopathology Core Curriculum in Molecular Biology
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 1 Molecular Basis of Cancer Molecular Oncology Keisha
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationat least 5 probes standard 8 probes (13, 15, 16, 18, 21, 22, 15, X, Y) at least 5 probes standard 8 probes (13, 15, 16, 18, 21, 22, X, Y)
Management of FISH probe testing Petra Musilová et al. Repromeda, Brno, Czech Rep. Veterinary Research Institute, Brno Genprogress, Brno, Czech Rep. Aneuploidy screening at least 5 probes standard 8 probes
More informationDetection of aneuploidy in a single cell using the Ion ReproSeq PGS View Kit
APPLICATION NOTE Ion PGM System Detection of aneuploidy in a single cell using the Ion ReproSeq PGS View Kit Key findings The Ion PGM System, in concert with the Ion ReproSeq PGS View Kit and Ion Reporter
More informationAbstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction
Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant
More informationKREATECH DIAGNOSTICS SOLID TUMORS
KREATECH DIAGNOSTICS SOLID TUMORS RF POSEIDON SOLUTIONS FOR SOLID TUMOR FISH DIAGNOSTICS TABLE OF CONTENTS Breast Cancer 3 Bladder Cancer 4 Cervical Cancer 4 Lung Cancer 5 Prostate Cancer 6 Thyroid Carcinoma
More informationMolecular pathology in soft tissue tumors. Sylvia Höller Pathologie
Molecular pathology in soft tissue tumors Sylvia Höller Pathologie When do we perform molecular testing? Morphology and IHC are not clearly fitting with an entity some translocations are entity specific
More informationGenomic analysis of childhood High grade glial (HGG) brain tumors
Genomic analysis of childhood High grade glial (HGG) brain tumors Linda D Cooley Children s Mercy, Kansas City The Children s Mercy Hospital, 2017 Genomic analysis of childhood High grade glial (HGG) brain
More informationAssessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray
Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray Hui Chen, Aysegul A Sahin, Xinyan Lu, Lei Huo, Rajesh R Singh, Ronald Abraham, Shumaila Virani, Bal Mukund Mishra, Russell Broaddus,
More informationmolecular oncology services
Molecular Oncology molecular oncology services ATIENTS.ANSWERS.RESULTS. www.aruplab.com/oncology MARCH 2018 Information in this brochure is current as of March 2018. All content is subject to change. lease
More informationXalkori. Xalkori (crizotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.12 Subject: Xalkori Page: 1 of 6 Last Review Date: June 22, 2017 Xalkori Description Xalkori (crizotinib)
More informationHematopathology Service Memorial Sloan Kettering Cancer Center, New York
SH2017-0334 t(14;18) Negative Follicular Lymphoma with 1p36 abnormality associated with In Situ Follicular Neoplasia with t(14;18) translocation Pallavi Khattar MD, Jennifer Maerki MD, Alexander Chan MD,
More informationMolecular pathology/genetics of sarcomas
Molecular pathology/genetics of sarcomas Gunhild Mechtersheimer Institute of Pathology, University of Heidelberg Sarkomkonferenz: 17.03.2011 Berlin Characterization of soft tissue sarcomas / STS (~ 1%
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationAssociation of molecular status and organs with metastases at diagnosis in patients with non-small cell lung cancer (NSCLC)
Association of molecular status and organs with metastases at diagnosis in patients with non-small cell lung cancer (NSCLC) Chantal Kuijpers* 1,2, Lizza Hendriks 3, Jules Derks 3, Anne-Marie Dingemans
More informationACMG/CAP Cytogenetics CY
www.cap.org Cytogenetics Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services ACMG/CAP Cytogenetics CY Analyte CY Challenges per Shipment
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
SW Thames Regional Genetics Laboratory, Jenner Wing, SGUL Cranmer Terrace London SW17 0RE Contact: Mr John Short Tel: +44 (0) 208 725 5332 Fax: +44 (0) 208 725 3440 E-Mail: swtrgl@stgeorges.nhs.uk Website:
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationDetection of Circulating Tumor Cells Harboring a Unique ALK-Rearrangement in ALK- Positive Non-Small-Cell Lung Cancer.
Detection of Circulating Tumor Cells Harboring a Unique ALK-Rearrangement in ALK- Positive Non-Small-Cell Lung Cancer Pailler, et al Data Supplement Table S1. Numbers and Percentages of ALK-Rearranged
More informationAliccia Bollig-Fischer, PhD Department of Oncology, Wayne State University Associate Director Genomics Core Molecular Therapeutics Program Karmanos
Aliccia Bollig-Fischer, PhD Department of Oncology, Wayne State University Associate Director Genomics Core Molecular Therapeutics Program Karmanos Cancer Institute Development of a multiplexed assay to
More informationIdentification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method
International journal of Biomedical science ORIGINAL ARTICLE Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method Martin K. H. Maus 1, 2, Craig Stephens
More informationPathologists role Ancillary Studies in Cytology Challenges. Pre-analytical issues. LUNG CYTOLOGY Predictive markers and molecular tests
Pathologists role LUNG CYTOLOGY Predictive markers and molecular tests Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Pathology Unit, IPATIMUP
More informationCYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING
INTRODUCTION The Cytogenetics Laboratory offers a comprehensive array of chromosome investigations for cancers, constitutional abnormalities, and prenatal and postnatal diagnosis. Analyses are performed
More informationStructural Variation and Medical Genomics
Structural Variation and Medical Genomics Andrew King Department of Biomedical Informatics July 8, 2014 You already know about small scale genetic mutations Single nucleotide polymorphism (SNPs) Deletions,
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 28
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationGENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute
GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help
More informationNationwide Children s Hospital Biospecimen Core Resource Training
Nationwide Children s Hospital Biospecimen Core Resource Training Team Science: A Collaboration in Medical Genomics Sponsored by the National Cancer Institute, the National Institutes of Health Nationwide
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationSALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.
mix P169-C2 HIRSCHSPRUNG-1 Lot C2-0915. As compared to version C1 (lot C1-0612), the length of one has been adjusted. Hirschsprung disease (HSCR), or aganglionic megacolon, is a congenital disorder characterised
More informationONCO TEAM DIAGNOSTIC
ONCO TEAM DIAGNOSTIC ONCO TEAM SPECIALISTS The team at ONCO TEAM has 23 specialists: o 11 general pathology seniors: - 8 PhD (1 PhD on lung tumors pathology) o 3 general pathology specialists; o 2 dermopathology
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Sarcoma with CIC-DUX4 gene fusion: case report of kidney tumor location in a 12-year-old boy. Perret Cécile 1, Pierron Gaelle 2, Anne Mc Leer 3, Piolat Christian
More informationWINTHER: GUSTAVE ROUSSY GUSTAVE ROUSSY. NOM DU DOCUMENT / Date
WINTHER Study Jean-Charles Soria, Razelle Kurzrock, Josep Tabernero, Apostolia Tsimberidou, Jordi Rodon, Raanan Berger, Amir Onn, Gerald Batist, Eitan Rubin, Yohann Loriot, Catherine Bresson, Vladimir
More informationMolecular Aspects of Melanocytic Neoplasia. Iwei Yeh MD, PhD University of California, San Francisco
Molecular Aspects of Melanocytic Neoplasia Iwei Yeh MD, PhD University of California, San Francisco Thanks to: Boris Bastian Timothy McCalmont Philip LeBoit Beth Ruben Jeff North Laura Pincus Thaddeus
More informationSALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.
SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. This SALSA probemix is for basic research only! This
More informationNucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis
Nucleic Acid Testing - Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Gross alterations in DNA content of tumors (ploidy) Gain/Loss of nucleic acids Markers of Clonality Oncogene/Tumor
More informationMolecular Diagnosis. Nucleic acid based testing in Oncology
Molecular Diagnosis Nucleic acid based testing in Oncology Objectives Describe uses of NAT in Oncology Diagnosis, Prediction, monitoring. Genetics Screening, presymptomatic testing, diagnostic testing,
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationZytoLight SPEC FGF3,4,19/CEN 11 Dual Color Probe
ZytoLight SPEC FGF3,4,19/CEN 11 Dual Color Probe The ZytoLight SPEC FGF3,4,19/CEN 11 Dual Color Probe is designed for the detection of amplifications of the chromosomal region harboring the genes FGF3,
More informationThe differential diagnosis between primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma
The differential diagnosis between primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma Daphne de Jong, MD PhD Amsterdam UMC, VU University Medical Center Amsterdam The Netherlands daphne.dejong@vumc.nl
More informationMRC-Holland MLPA. Description version 18; 09 September 2015
SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationDisclosure of Relevant Financial Relationships
Ewing and Ewing like sarcomas Using Genetic Signatures in Refining Small Blue Round Cell Tumor Classification Cristina Antonescu, MD Department of Pathology Disclosure of Relevant Financial Relationships
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationClinical Cytogenomics Laboratory. Laboratory. Leading diagnostics for better medicine. Beaumont
Clinical Cytogenomics Laboratory Leading diagnostics for better medicine Beaumont Laboratory Beaumont Laboratory s Clinical Cytogenomics Lab Genome decoding is essential Knowledge of variations in genome
More informationIT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm
I N T E R P R E TAT I O N IQFISH pharmdx Interpretation Guide TM HER2 IQFISH pharmdxtm TOP2A IQFISH pharmdxtm Breast carcinoma (FFPE) stained with HER2 IQFISH pharmdx Breast carcinoma (FFPE) stained with
More informationUse of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma
Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma Dr Anthony Bench Haematopathology and Oncology Diagnostic Service Cambrıdge Unıversıty Hospitals NHS Foundatıon Trust Cambridge
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationOrganisational challenges faced by Bristol Genetics in the past 18 months
Organisational challenges faced by Bristol Genetics in the past 18 months Stuart Cook Introduction 1. The move towards 7-day working 2. Transitioning to a new lab facility 3. Improving process efficiency
More information